Driven by volume-based procurement, tiered healthcare system and technological innovation, China’s in vitro diagnostic (IVD) industry is shifting from scale expansion to high-quality development, with domestic substitution entering an in-depth phase. In terms of policies, the regular implementation of volume-based procurement and DRG/DIP reforms forces accelerated industrial consolidation. Profit margins of homogeneous low-end products are …
It often starts with big promises and ends in bitter disputes. The friction between IVD manufacturers and overseas distributors isn’t just about bad tempers—it’s a systemic clash across four critical dimensions: business models, profit distribution, regulatory ownership, and service capabilities. Key Conflict Points 1. Price & Margin Squeeze Manufacturers want profit margins to offset domestic …
Why IVD Manufacturers and Overseas Distributors Keep Falling Out？ Read More »
The survival-of-the-fittest dynamic within the industry is no longer a matter of prediction but an ongoing reality. Data indicate that the number of IVD enterprises in China has declined precipitously in recent years: – In 2023, approximately 2,320 IVD enterprises operated in China. By 2025, this figure had plummeted to roughly 1,530—meaning nearly 800 enterprises …
